^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SJCAR19

    i
    Other names: SJCAR19, CD19- specific CAR engineered autologous T-cells, SJCAR-19, SJCAR 19
    Associations

    News

    Trials
    Company:
    St. Jude Children's Research Hospital
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    23d
    Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2024 --> Jul 2025
    Trial completion date
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • mesna • SJCAR19
    over1year
    Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=35, Recruiting, St. Jude Children's Research Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • SJCAR19
    almost2years
    Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=35, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • SJCAR19